CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Melt Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Melt Pharmaceuticals Inc
5511 Virginia Way, Suite 300
Phone: (858) 704-4042p:858 704-4042 BRENTWOOD, TN  37027  United States
Business Summary
Melt Pharmaceuticals Inc is a United States-based clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of non-opioid, non-IV, sedation and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings. Its product candidate pipeline consists of: MELT-300, is a lead product candidate, which is a fixed dose combination of midazolam and ketamine in a fast-dissolving tablet that is administered sublingually for procedural sedation and analgesia during cataract surgery; MELT-210, which is a fixed dose of midazolam in a fast-dissolving tablet that is administered sublingually for procedural sedation for short duration procedures; and MELT-400, which is a fixed dose of ketamine in a fast-dissolving tablet that is administered sublingually for short-term or acute pain. The Company is a wholly owned subsidiary of Harrow Health, Inc. formerly Imprimis Pharmaceuticals, Inc. (Harrow).
(Source: PROSPECTUS)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202212/31/2021YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Nominee Chairman of the Board Mark L.Baum 50 1/1/2023 4/1/2018
Chief Executive Officer, Director Larry M.Dillaha 59 6/1/2021 6/1/2021
Chief Financial Officer D. B.Osborne 43 2/1/2022 2/1/2022
5 additional Officers and Directors records available in full report.

General Information
Number of Employees: 3 (As of 6/30/2022)
Outstanding Shares: 5,395,311 (As of 9/21/2022)
Federal Tax Id: 611888986


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, October 24, 2024